Clinical trial of acetazolamide in SCA6, with assessment using the Ataxia Rating Scale and body stabilometry

OBJECTIVE: To investigate the effect of acetazolamide on spinocerebellar ataxia type 6 (SCA6). METHODS: Acetazolamide (250-500 mg/day) was administered orally for 88 weeks to 6 patients with SCA6, and its effect was quantitatively monitored using the Ataxia Rating Scale (ARS) and body sway analysis by stabilometry. RESULTS: During administration of acetazolamide, the ARS score and the amplitude of body sway were significantly reduced compared with before administration. However, the response became weaker after 1 year of treatment. CONCLUSION: Although this was an open trial, the results suggested that acetazolamide can temporarily reduce the severity of symptoms during the progression of SCA6.